# Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2014

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2015-01-09
- Accepted by EDGAR: Jan 9, 2015, 17:10 ET
- Period: 2014-11-30
- Accession: 0001275187-15-000009
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000127518715000009/ango-113014x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000127518715000009/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-11-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-09-01 to 2014-11-30 | $92.1m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2014-06-01 to 2014-11-30 | $179.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-09-01 to 2014-11-30 | $44.5m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2014-06-01 to 2014-11-30 | $86.0m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2014-09-01 to 2014-11-30 | $47.7m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2014-06-01 to 2014-11-30 | $93.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2014-09-01 to 2014-11-30 | $6.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2014-06-01 to 2014-11-30 | $12.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2014-09-01 to 2014-11-30 | $4.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-06-01 to 2014-11-30 | $7.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-09-01 to 2014-11-30 | $793.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2014-06-01 to 2014-11-30 | $1.6m | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-09-01 to 2014-11-30 | $1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2014-06-01 to 2014-11-30 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-09-01 to 2014-11-30 | $1.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2014-06-01 to 2014-11-30 | $1.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-09-01 to 2014-11-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2014-06-01 to 2014-11-30 | $0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-09-01 to 2014-11-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2014-06-01 to 2014-11-30 | $0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-09-01 to 2014-11-30 | 36,127,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2014-06-01 to 2014-11-30 | 36,012,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months, 2014-06-01 to 2014-11-30 | $7.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-11-30 | $14.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-11-30 | $163.4m | us-gaap:AssetsCurrent |
| Total assets | at 2014-11-30 | $799.3m | us-gaap:Assets |
| Current liabilities | at 2014-11-30 | $57.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-11-30 | $255.8m | us-gaap:Liabilities |
| Current portion of debt | at 2014-11-30 | $6.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2014-11-30 | $543.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 26,328 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC, including our Form 10-K/A for the fiscal year ended May 31, 2014.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### Overview

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use.

We sell our products in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. For the three months ended November 30, 2014 and 2013, approximately 21% and 20%, respectively, of our net sales were from markets outside the United States.

Our sales and profitability growth depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. In recent years we have acquired or developed, and launched several new products, including the AngioVac cannula and circuit, the BioFlo family of products, and the Acculis microwave system, which are all expected to be growth drivers of our business. We recognize the importance of, and intend to continue to make investments in, research and development activities and business development opportunities.

Our ability to further increase our profitability will depend in part on improving gross profit and operating margins. A portion of improved gross margin we expect to deliver through the acquisition, development and sale of innovative products, such as those mentioned above. Additionally, in December 2013 we announced a company-wide operational excellence program designed to create greater efficiencies and drive improved business performance. Further, we anticipate being able to manage increases in our operating expenses at a rate slower than our sales growth to provide further operating margin expansion.

### Immaterial Error Corrections

During the financial closing process for the first quarter of fiscal year 2015, the Company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The Company has identified amounts and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. Although management has determined the amounts individually and in the aggregate are not material to prior periods, in accordance with authoritative accounting literature on considering the effects of misstatements in prior years when quantifying misstatements in the current year, the financial statements included herein have been adjusted to correct for the impact of these items.

The Company has corrected the relevant financial information from previous reporting periods contained in these financial statements. The immaterial error corrections identified were primarily related to our failure to recognize the expense associated with prepaid and other assets in accordance with the underlying contractual terms (cumulative impact of approximately $1.2 million) and depreciation expense (cumulative impact of approximately $0.4 million), and other individually immaterial items. Also, approximately $5.4 million of contingent consideration liabilities that had been classified as current are classified as long term in the balance sheet.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note N to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations for the Three Months ended November 30, 2014 and November 30, 2013

For the three months ended November 30, 2014, we reported net income of $1.3 million, or $0.04 per diluted share, on net sales of $92.1 million, compared with a net loss of $261 thousand, or $(0.01) per share, on net sales of $88.6 million during the same quarter of the prior year.

The table below presents certain operating data as a percentage of net sales:

|  | Three Months Ended Nov 30, 2014 | Nov 30, 2013 As revised |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 51.7% | 50.7% |
| Research and development | 6.6% | 7.9% |
| Sales and marketing | 22.8% | 23.8% |
| General and administrative | 8.7% | 7.2% |
| Amortization of intangibles | 4.4% | 4.9% |
| Change in fair value of contingent consideration | 0.7% | 1.1% |
| Acquisition, restructuring and other items, net | 2.5% | 3.0% |
| Medical device excise tax | 1.2% | 1.1% |
| Operating income | 5.0% | 1.6% |
| Other income (expenses) | (1.9)% | (2.0)% |
| Income taxes | 1.6% | (0.1)% |
| Net income (loss) | 1.5% | (0.3)% |

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns. For the three months ended November 30, 2014, net sales increased $3.6 million to $92.1 million compared to the same period in the prior year. Our sales grew in all product lines and in both the U.S. and International markets. This growth was partially offset by decreased sales through our supply agreement arrangement.

From a product line perspective, Peripheral Vascular sales increased $0.6 million or 1% from the prior year period to $49.4 million. This increase was primarily attributable to the AngioVac product line. Vascular Access sales were $28.0 million, an increase of $2.4 million or 9% from the prior year period. This increase is attributable to increased sales of our Bioflo family of products, and specifically our port products. Oncology/Surgery sales were $13.6 million, an increase of 9% from prior year quarter sales of $12.6 million, primarily due to increased sales of our microwave and NanoKnife products.

From a geographic perspective, U.S. sales increased $2.6 million or 4% during the second three months of fiscal 2015 to $72.1 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of AngioVac and Bioflo products. International sales were $19.0 million in the fiscal second quarter of 2015, an increase of 9% from $17.5 million in the comparable prior year period. The increase is attributable to increased sales of Nanoknife and

Vascular Access products. Our supply agreement arrangement, which we do not include in either the U.S. or International geographic sales, declined 32.0% to $1.1 million from $1.6 million in the prior year period.

Changes in sales are driven primarily by increases in volume.

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Our gross profit as a percentage of sales increased from 50.7% in the prior year period to 51.7% during the three months ended November 30, 2014. The increase is largely attributable to improved operating efficiencies and a more profitable mix of products sold created by our growth drivers.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs and our intellectual property. For both the three months ended November 30, 2014 and 2013, R&D expenses were $6.1 million and $7.0 million, respectively. As a percentage of net sales, R&D expenses were 6.6% and 7.9% for the second quarters of fiscal years 2015 and 2014, respectively. The decrease in R&D costs relates to savings generated by restructuring activities in the first quarter of fiscal 2015, as well as timing of projects.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses decreased $0.1 million during the three months ended November 30, 2014 to $20.1 million when compared to the same period in the prior year. As a percentage of net sales, S&M expenses decreased to 22.8% in the fiscal second quarter of 2015, from 23.8% for the prior year period.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses increased $1.6 million, or 24.4%, to $8.0 million when compared to the same period in the prior year. G&A expenses increased to 8.7% of net sales from 7.2% in the prior year period. The increase is primarily a result of costs associated with the implementation of our ERP system and stock-based compensation.

Amortization of intangibles - Amortization of intangibles decreased $0.2 million to $4.1 million during the period.

Change in fair value of contingent consideration - The second quarter of fiscal 2015 included accretion of $0.6 million in the change in fair value of the contingent consideration associated with the business acquisitions compared with $0.9 million in the prior year period.

Acquisition, restructuring and other items, net - The second quarter of fiscal 2015 included Acquisition, restructuring and other items, net expenses of $2.3 million compared to $2.7 million in the prior year period, which primarily consistent of costs associated with our operational excellence program, litigation expense, and restructuring in our finance and international S&M organizations.

Medical device excise tax - The second quarter of fiscal 2015 and 2014 included $1.1 million and $1.0 million, respectively, attributable to the Medical Device Excise Tax.

Operating income - During the three months ended November 30, 2014, operating income increased $3.1 million to $4.6 million. As a percentage of sales, operating income was 5.0% and 1.6% for the three months ended November 30, 2014 and 2013, respectively.

Other expenses - Other expenses for the three months ended November 30, 2014 and 2013 were $1.7 million and $1.8 million, respectively.

Income taxes - Our effective tax rate including discrete items was 53% for the second fiscal quarter of 2015 compared with a 25% effective tax rate benefit for the prior year period. The current quarter reflects no benefit from the expired R&D tax credit. The prior year quarter reflects a seven month benefit from the R&D tax credit that had previously expired on December 31, 2013 and a benefit from lower tax rates applicable to our foreign operations, partially offset by non-deductible interest expense on contingent payments.

In addition, our ASC 718 APIC pool was fully depleted in the quarter ended November 30, 2014 and 2013. Prior to its depletion, the APIC pool was reduced when share-based compensation cost previously recognized was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting. Due to its depletion, we recorded a discrete tax expense of $330 thousand and $61 thousand in the three months ended November 30, 2014 and 2013, respectively.

During the fiscal third quarter of 2014, The Tax Increase Prevention Act of 2014 (H.R. 5771) was enacted and retroactively extended the research credit from January 1, 2014 to December 31, 2014. Accordingly, the retroactive benefit related to this renewal will be reflected in our third quarter results.

Net income (loss) - For the three months ended November 30, 2014, we reported net income of $1.3 million, compared to a net loss of $0.3 million for the same period in the prior year.

### Results of Operations for the Six Months ended November 30, 2014 and November 30, 2013

For the six months ended November 30, 2014, we reported net income of $1.8 million, or $0.05 per diluted share, on net sales of $179.5 million, compared with a net loss of $634 thousand, or $(0.02) per share, on net sales of $172.2 million during the same period of the prior year.

The table below presents certain operating data as a percentage of net sales:

|  | Six Months Ended Nov 30, 2014 | Nov 30, 2013 As revised |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 52.1% | 50.8% |
| Research and development | 7.1% | 8.0% |
| Sales and marketing | 22.9% | 23.8% |
| General and administrative | 8.5% | 7.5% |
| Amortization of intangibles | 4.5% | 5.0% |
| Change in fair value of contingent consideration | 0.8% | 1.0% |
| Acquisition, restructuring and other items, net | 2.8% | 2.7% |
| Medical device excise tax | 1.2% | 1.1% |
| Operating income | 4.4% | 1.7% |
| Other income (expenses) | (2.0)% | (2.2)% |
| Income taxes | 1.4% | (0.2)% |
| Net income (loss) | 1.0% | (0.4)% |

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns. For the six months ended November 30, 2014, net sales increased $7.3 million to $179.5 million when compared to the same period in the prior year. Our sales grew in all product lines and in both the U.S. and International markets. This growth was partially offset by decreased sales through our supply agreement arrangement.

From a product line perspective, Peripheral Vascular sales increased $2.4 million or 3% from the prior year period to $96.8 million. This increase was primarily attributable to the AngioVac product line. Vascular Access sales were $54.4 million, an increase of $3.5 million or 7% from the prior year period. This increase is attributable to increased sales of our Bioflo family of products, and specifically our port products. Oncology/Surgery sales were $26.0 million, an increase of 10% from prior year period sales of $23.7 million, led by increased sales of our NanoKnife products.

From a geographic perspective, U.S. sales increased $3.8 million or 3% during the first six months of fiscal 2015 to $140.4 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of AngioVac and port products. International sales were $36.8 million in the first six months of fiscal 2015, an increase of 14% from $32.3 million in the comparable prior year period. The increase is attributable to increased sales of fluid management, microwave and Nanoknife. Our supply agreement arrangement, which we do not include in either the U.S. or International geographic sales, declined 30% to $2.3 million from $3.3 million in the prior year period.

Changes in sales are driven primarily by increases in volume.

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Our gross profit as a percentage of sales increased from 50.8% in the prior year period to 52.1% during the six months ended November 30, 2014. The increase is largely attributable to improved operating efficiencies and a more profitable mix of products sold created by our growth drivers.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs and our intellectual property. For the six months ended November 30, 2014 and 2013, R&D expenses were $12.8 million and $13.7 million, respectively. As a percentage of net sales, R&D expenses were 7.1% and 8.0% for the first six months of fiscal years 2015 and 2014, respectively. The decrease in R&D costs relates to savings generated by restructuring activities in the first quarter of fiscal 2015, as well as timing of projects.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses remained consistant during the six months ended November 30, 2014 and 2013. As a percentage of net sales, S&M expenses decreased to 22.9% in the first six months of fiscal 2015, from 23.8% for the prior year period.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses increased $2.4 million, or 18.4% for the six months ended November 30, 2014, to $15.3 million when compared to the same period in the prior year. G&A expenses increased to 8.5% of net sales from 7.5% in the prior year period. The increase is primarily a result of costs associated with the implementation of our ERP system and stock-based compensation.

Amortization of intangibles - Amortization of intangibles decreased $0.5 million to $8.1 million during the period.

Change in fair value of contingent consideration - The first six months of fiscal 2015 included accretion of $1.4 million in the change in fair value of the contingent consideration associated with the business acquisitions compared with $1.7 million in the prior year period.

Acquisition, restructuring and other items, net - The first six months of fiscal 2015 included Acquisition, restructuring and other items, net expenses of $5.0 million compared to $4.7 million in the prior year period, which primarily consisted severance expense related to the reorganization of our International S&M organization, costs related to our operational excellence program and litigation expense and other items.

Medical device excise tax - The first six months of fiscal 2015 and 2014 included $2.1 million and $2.0 million, respectively, attributable to the Medical Device Excise Tax.

Operating income - During the six months ended November 30, 2014, operating income increased $5.0 million to $7.8 million. As a percentage of sales, operating income was 4.4% and 1.7% for the six months ended November 30, 2014 and 2013, respectively.

Other expenses - Other expenses for the six months ended November 30, 2014 and 2013 were $3.6 million and $3.8 million, respectively.

Income taxes . Our effective tax rate including discrete items was 58% for the first six months of fiscal 2015 compared with 31% benefit for the prior year period. The current period reflects no benefit from the expired R&D tax credit.

The prior year period reflects a seven month benefit from the R&D tax credit that expired on December 31, 2013 and a benefit from lower tax rates in foreign jurisdictions in which we operate, offset by non-deductible interest expense related to contingent payments.

In addition, our ASC 718 APIC pool was fully depleted in the six months ended November 30, 2014 and 2013. Prior to its depletion, the APIC pool was reduced when share-based compensation cost previously recognized was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting. Due to its depletion, we recorded a discrete tax expense of $684 thousand and $61 thousand in the six months ended November 30, 2014 and 2013, respectively.

During the fiscal third quarter of 2014, The Tax Increase Prevention Act of 2014 (H.R. 5771) was enacted and retroactively extended the research credit from January 1, 2014 to December 31, 2014. Accordingly, the retroactive benefit related to this renewal will be reflected in our third quarter results.

Net income (loss) - For the six months ended November 30, 2014, we reported net income of $1.8 million, compared to a net loss of $0.6 million for the same period in the prior year.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $14.9 million as of November 30, 2014, compared with $16.1 million as of May 31, 2014. Marketable securities totaled $1.7 million and $1.8 million as of November 30, 2014 and May 31, 2014, respectively, and consist of auction rate securities. As of November 30, 2014, total debt was $155 million primarily comprised of short and long-term bank debt. The fair value of contingent milestone payments as of November 30, 2014 was $57.4 million.

The table below summarizes our cash flows for the six months ended November 30, 2014 and 2013 (in thousands of dollars):

| Cash provided by (used in): | Six Months Ended Nov 30, 2014 | Nov 30, 2013 As revised |
| --- | ---: | ---: |
| Operating activities | $3,205 | $15,758 |
| Investing activities | (7,773) | (11,207) |
| Financing activities | 3,381 | (11,184) |
| Effect of exchange rate changes on cash and cash equivalents | (41) | 4 |
| Net change in cash and cash equivalents | $(1,228) | $(6,629) |

Net cash provided by operating activities during the six months ended November 30, 2014 and 2013 was $3.2 million and $15.8 million, respectively. Cash provided by operating activities during the six months ended November 30, 2014, was primarily the result of an increase of $2.5 million in tax deferrals, increases in non-cash expenses such as share based compensation in the six month period ended November 30, 2014 compared to the prior year period. During the six months ended November 30, 2014 we experienced cash outflows due to increased inventories coupled with a reduction in accounts payable and accrued liabilities partially offset by a decrease in accounts receivable.

Net cash used in investing activities during the six months ended November 30, 2014 and 2013 was $7.8 million and $11.2 million, respectively. The net cash used in investing activities for the current year period consisted primarily of fixed asset additions. The prior year use of cash consisted primarily of the Clinical Devices acquisition and fixed asset additions.

Net cash provided by (used in) financing activities during the six months ended November 30, 2014 and 2013 was $3.4 million and ($11.2) million, respectively. The current year period consisted primarily of borrowings on the revolver and proceeds from the exercise of stock options and purchases related to our employee stock purchase plan, offset by a scheduled debt payment and payment of contingent consideration related to the acquisition of Microsulis .

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially from that disclosed in our Annual Report on Form 10-K/A for our fiscal year ended May 31, 2014.

We believe that our current cash and investment balances, together with cash generated from operations and our remaining revolving credit facility capacity of $38.6 million as of November 30, 2014, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.

## Market risk

As filed, 1,311 characters.

We are exposed to market risk from changes in interest rates on investments and financing that could impact our results of operations and financial position. Although we have entered into interest rate swaps with a bank to limit our exposure to interest rate change on our variable interest rate financings, we do not currently engage in any other hedging or market risk management tools.

The majority of our sales have historically been denominated in United States dollars. Although not significant, we transact sales in other currencies, particularly the Euro, British pound and Canadian dollar. We currently have limited direct foreign currency exchange risk.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities (“ARS”) in order to generate higher than typical money market investment income. ARS typically are high credit quality, generally achieved with municipal bond insurance and credit risk is eased by the historical track record of bond insurers, which back a majority of this market.

## Controls and procedures

As filed, 6,803 characters.

### Evaluation of disclosure controls and procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based solely on the definition of "disclosure controls and procedures" in Rule 13a-15(e) promulgated under the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision of our Company’s Chief Executive Officer and Chief Financial Officer, we carried out an evaluation of our disclosure controls and procedures as of August 31, 2014. At the time our Annual Report on Form 10-K/A for the year ended May 31, 2014 was filed on August 14, 2014, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of May 31, 2014. Subsequent to that evaluation, in assessing the control deficiencies that contributed to the immaterial error corrections described in Note A and Note P which were identified during our financial close process for the period ended August 31, 2014, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of May 31, 2014 and November 30, 2014 because of the material weaknesses in our internal control over financial reporting described below.

A material weakness is a deficiency, or a combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

*We did not maintain effective controls over the preparation, review and approval of certain account reconciliations. Specifically, the Company did not maintain effective controls over the completeness and analysis of supporting schedules and underlying data supporting account reconciliations prepared for certain prepaid expenses and other assets and fixed assets and accumulated depreciation.*

*We lacked a sufficient complement of personnel with a level of financial reporting expertise commensurate with our financial reporting requirements, specifically, with respect to resources capable of: monitoring and accurately recording certain routine transactions specifically in prepaid expenses and other assets, fixed assets and accumulated depreciation; evaluating the presentation and disclosure of contingent consideration liabilities and intangible assets; effectively performing testing related to our enterprise resource planning ("ERP") implementation specifically associated with the configuration of certain intercompany transactions and the conversion of data related to depreciation; and properly performing account reconciliations as noted above.*

These material weaknesses resulted in the revision to our previously reported interim and annual financial statements for the fiscal year ended May 31, 2014 and for the fiscal years ended May 31, 2013, 2012, and 2011, as described in Note P of this Quarterly Report. Accordingly, the Company amended its Annual Report on Form 10-K for the year ended May 31, 2014 to reflect the conclusion by the Company's management that internal control over financial reporting and disclosure controls and procedures were not effective as of May 31, 2014.

These material weaknesses could result in misstatements that would result in a material misstatement of the consolidated financial statements that would not be prevented or detected.

In response to these material weaknesses, our management performed additional analysis and procedures, including enhanced business performance reviews and analysis, in order to conclude that despite the material weaknesses reported above, the consolidated financial statements included in this report fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented and that this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

### Remediation Plan

During the quarter ended August 31, 2014, we developed a plan to enhance our internal controls over financial reporting, which we believe also will address the material weaknesses discussed above, including the specific remediation initiatives described below:

- Enhancing our internal finance and accounting organizational structure, which includes changes to personnel in place as of May 31, 2014 and hiring additional resources.
- Strengthening our internal policies and processes, including training for personnel, for ensuring account reconciliations are completed and reviewed properly.
- Continued investments in our ERP to improve the transactional accounting and processes supporting the recording of certain routine transactions.

As part of this plan, the following steps were taken during our first six months of our fiscal year ended May 31, 2015:

- Hired additional full-time and temporary accounting resources with appropriate levels of experience, including a new Global Controller, Assistant Controller and Senior Accounting Manager to drive improvement of and oversee day-to-day accounting activities.
- Implemented an account reconciliation policy.
- Added financial planning and analysis resources to strengthen to overall internal control environment.
- Commenced a detailed review of our ERP to identify opportunities to improve the accuracy of routine transaction processing, specifically with respect to accounting transactions related to purchasing and payables.

### Changes in Internal Control over Financial Reporting

Other than items described above related to steps taken under our remediation plan during the quarter, there was no change in our internal control over financial reporting in the six months ended November 30, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,989 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K/A for our fiscal year ended May 31, 2014 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K/A, except for the following related to our internal controls:

**We have determined that material weaknesses exist in our internal control over financial reporting which could, if not remediated, have a material adverse impact on our ability to produce timely and accurate financial statements.**

We are responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act. As discussed in Part I - Item 4, we identified material weaknesses in our internal control over financial reporting as of May 31, 2014. Solely as a result of these material weaknesses, management concluded that our internal control over financial reporting was not effective as of May 31, 2014.

A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Although we continue to devote significant time and attention to remedy the identified material weaknesses in internal control over financial reporting, we expect to complete our remediation plan and testing of the remediated controls during the fiscal year ended May 31, 2015. There is the potential that our remedial efforts may not be successful. Until our remediation plan is fully implemented, our management will continue to devote significant time and attention to these efforts. If we do not complete our remediation in a timely fashion, or at all, or if our remediation plan is inadequate or we encounter difficulties in the implementation or maintenance of our internal control over financial reporting or disclosure controls and procedures, there will continue to be an increased risk that we will be unable to timely file future periodic reports with the SEC and/or remain in compliance with certain covenants included in our outstanding debt agreements. In addition, any failure to implement or any difficulties we encounter with our remediation plan could result in additional material weaknesses or deficiencies in our internal control or future material misstatements in our annual or interim consolidated financial statements.

Filed Jan 9, 2015.
Source: SEC EDGAR, the filing index for accession 0001275187-15-000009. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
